EGFR and non-small cell lung carcinoma: This review introduces the progress of research on the use of ctDNA/cfDNA in the precision treatment of EGFR-mutated NSCLC, including the screening of therapeutic targets, the analysis of resistance mechanisms, and the monitoring of minimal residual disease (MRD).